VSPharmTech

1. Company Overview
VSPharmTech, a clinical-stage biotech company, aims to advance life-saving drugs and healthcare solutions, particularly in cancer therapeutics. Currently, we have 3 pipelines-radiosensitizer, chemosensitizer, and cancer metastasis inhibitor.
2. VSPharmTech Pipelines
1) VS-101: A radiosensitizer for patients with various solid cancers requiring radiotherapy. Combining it with radiotherapy enhances efficacy and lowers toxicity compared to standard radiotherapy. It is safe because it is developed by repurposing a drug that has been widely used in various indications over 20 years since the FDA approval. Currently in phase 1 trials in South Korea, it received FDA approval for phase 2 trials in the US in July 2023.
2) VS-501: An anticancer drug with a new mechanism that inhibits cancer metastasis by inhibiting invasion and immigration of cancer deaths. As a first-in-class drug, it represents a new option for combating cancer metastasis.